• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Biomol Struct Dyn . In silico exploration of small-molecule α-helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2

tetano

Editor, Senior Moderator
J Biomol Struct Dyn


. 2020 Oct 7;1-12.
doi: 10.1080/07391102.2020.1830175. Online ahead of print.
In silico exploration of small-molecule α-helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2


Mohammed Hakmi[SUP] 1 [/SUP], E L Mehdi Bouricha[SUP] 1 [/SUP], Jihane Akachar[SUP] 1 [/SUP], Badreddine Lmimouni[SUP] 2 [/SUP], Jaouad El Harti[SUP] 3 [/SUP], Lahcen Belyamani[SUP] 4 [/SUP], Azeddine Ibrahimi[SUP] 1 [/SUP]



Affiliations

Abstract

The novel coronavirus, SARS-CoV-2, has infected more than 10 million people and caused more than 502,539 deaths worldwide as of June 2020. The explosive spread of the virus and the rapid increase in the number of cases require the immediate development of effective therapies and vaccines as well as accurate diagnosis tools. The pathogenesis of the disease is triggered by the entry of SARS-CoV-2 via its spike protein into ACE2-bearing host cells, particularly pneumocytes, resulting in overactivation of the immune system, which attacks the infected cells and damages the lung tissue. The interaction of the SARS-CoV-2 receptor binding domain (RBD) with host cells is primarily mediated by the N-terminal helix of ACE2; thus, inhibition of the spike-ACE2 interaction may be a promising therapeutic strategy for blocking the virus entry into host cells. In this paper, we used an in-silico approach to explore small-molecule α-helix mimetics as inhibitors that may disrupt the attachment of SARS-CoV-2 to ACE2. First, the RBD-ACE2 interface in the 6M0J structure was studied by the MM-GBSA decomposition module of the HawkDock server, which led to the identification of two critical target regions in the RBD. Next, two virtual screening experiments of 7236 α-helix mimetics from ASINEX were conducted on the above regions using the iDock tool, which resulted in 10 candidates with favorable binding affinities. Finally, the stability of RBD complexes with the top-two ranked compounds was further validated by 100ns of molecular dynamics simulations. Communicated by Ramaswamy H. Sarma.

Keywords: ACE2; COVID-19; Coronavirus; MD simulation; SARS-COV-2; spike; treatment; virtual screening; α-helix mimetics.
 
Back
Top Bottom